Third Quarter Financial Results on Form 6-K
Filed with ASX · · 102 pages · English
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings CallSilviu Itescu Chief Executive Officer and Executive Director Level 38 55 Collins Street Melbourne 3000 Australia (Address of principal executive offices) ________________________________________ Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-FxForm 40-Fo Page Incorporation by Reference 3 Currency of Presentation and Certa
In the deck
Story so far
Earlier from Mesoblast
- Reinstatement to Official Quotation
- Mesoblast Completes Private Placement
- Voluntary Suspension
- FDA Accepts Mesoblasts BLA Resubmission for Remestemcel-L
- DREAM HF Trial Published in JACC
Later from Mesoblast
- MSB Reports Q3 Financial Results and Operational Highlights
- Update on BLA for Graft Versus Host Disease
- MSB Launches Entitlement Offer and Placement
- Entitlement Offer and Placement Investor Presentation
- Mesoblast Completes Institutional Allocation
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast